CytoReason and Ferring Pharmaceuticals announced a collaboration that pairs CytoReason’s artificial intelligence (AI)-based computational model of the human body with Ferring’s expertise in inflammatory bowel disease (IBD). The purpose is to develop cell-based disease models to accelerate drug discovery and reduce development costs.
In a groundbreaking study, scientists at Harvard University identified an enzyme that seems to dictate the limits of human physical performance.
A look at which parts of the body the novel coronavirus infects and how SARS-CoV-2 is transmitted from person to person.
At least 10 different drug compounds ranging from cancer therapies to antipsychotics and antihistamines may be effective at preventing the new coronavirus from multiplying in the body, according to a multidisciplinary study conducted by a team of scientists in the United States and France.
Nurix Therapeutics Inc. is developing drugs that can specifically target one protein within the hundreds or thousands of extremely similar proteins in the body, ultimately enabling them to regulate hard-to-drug or ‘undruggable’ proteins.
Results from NASA’s landmark Twins Study reveals some interesting, surprising and reassuring data.